We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)’s share was ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Eli Lilly's recent leadership transitions could bolster its strategic focus on global market expansion, potentially impacting its revenue and earnings forecasts. The company aims to enhance its ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

INDIANAPOLIS — Over the next eight years, Eli Lilly and Company and Purdue University will continue their partnership. According to an announcement on Friday morning, Lilly is expected to invest ...

Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it. The company's results, underlying business, and long-term prospects remain incredibly attractive.

Recent clinical trial results Eli Lilly released suggest that it is building a lead in the weight loss space. Should investors buy the company's shares? Let's find out. In December, Eli Lilly ...